Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a competent, adult caregiver(s) who is able to recognize and observe the subject's seizure cluster episodes~2. Has an established diagnosis of partial or generalized epilepsy that includes all the following:~   * A documented history of seizure clusters lasting a minimum of 10 minutes, seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any)~  * A second seizure in the seizure cluster typically occurs within 6 hours from the time of recognition~  * A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures~  * A seizure cluster pattern established \>3 months before Visit 1~  * A frequency of ≥ 3 stereotyped seizure clusters during the year before Visit 1~  * At least 1 stereotyped seizure cluster occuring ≤ 4 months before Visit 1~3. Currently on a stable regimen of AED(s) that includes a benzodiazepine~4. Weight is 40 kg to 125 kg, inclusive~Exclusion Criteria:~1. Has a neurological disorder that is likely to progress in the next year~2. Has a severe chronic cardio-respiratory disease~3. Has a psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1~4. Has a history of their stereotypical seizure cluster progressing to status epilepticus within 2 years before Visit 1~5. Has a history of acute narrow-angle glaucoma~6. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- USL261 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).